Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62]

Satoshi Watanabe¹, Hiroshige Yoshioka², Hiroshi Sakai³, Katsuyuki Hotta⁴, Mitsuhiro Takenoyama⁵, Kazuhiko Yamada⁶, Shunichi Sugawara⁷, Yuichi Takiguchi⁸, Yukio Hosomi⁹, Keisuke Tomii¹⁰, Seiji Niho¹¹, Nobuyuki Yamamoto¹², Makoto Nishio¹³, Yuichiro Ohe¹⁴, Terufumi Kato¹⁵, Toshiaki Takahashi¹⁶, Ami Kamada¹⁷, Kazumi Suzukawa¹⁷, Yukie Omori¹⁷, Sotaro Enatsu¹⁷, Kazuhiko Nakagawa¹⁸, Tomohide Tamura¹⁹

Affiliations

¹ Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 8050 Ikarashi 2-no-cho, Nishi-ku, Niigata, 950-2181, Japan.
² Department of Respiratory Medicine, Kurashiki Central Hospital, 1 Chome-1-1 Miwa, Kurashiki, 710-8602, Japan.
³ Division of Thoracic Oncology, Saitama Cancer Center, 780 Komuro, Ina, Kitaadachi District, Saitama, 362-0806, Japan.
⁴ Department of Allergy and Respiratory Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital, 2 Chome-5-1 Shikatacho, Kita, Okayama, 700-8558, Japan.
⁵ Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 3 Chome-1-1 Notame, Minami Ward, Fukuoka, 811-1395, Japan.
⁶ Department of Internal Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka Prefecture, 830-0011, Japan.
⁷ Department of Pulmonary Medicine, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba Ward, Sendai, Miyagi Prefecture, 980-0873, Japan.
⁸ Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
⁹ Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3 Chome-18-22, Bunkyō-ku, Honkomagome, 113-0021, Tokyo, Japan.
¹⁰ Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2 Chome-1-1 Minatojima Minamimachi, Chuo Ward, Kobe, Hyōgo Prefecture, 650-0047, Japan.
¹¹ Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba-ken, 277-8577, Japan.
¹² Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, WakayamaPrefecture, 641-8509, Japan.
¹³ Department of Thoracic Medical Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.
¹⁴ Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
¹⁵ Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6 Chome-16-1 Tomiokahigashi, Kanazawa-ku, Yokohama-shi, Kanagawa, 236-0051, Japan.
¹⁶ Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
¹⁷ Medical Affairs, Eli Lilly Japan K.K., 7-1-5 Isogamidori, Chuo-Ku, Kobe, 651-0086, Japan.
¹⁸ Department of Medical Oncology, Kindai University Faculty of Medicine, 3-4-1 Kowakae, Higashiosaka City, Osaka, 577-8502, Japan.
¹⁹ Thoracic Center, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan. Electronic address: tamuratomohide@gmail.com.

PMID: 31014853
DOI: 10.1016/j.lungcan.2019.04.010

Free article

Published Erratum

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62]

Satoshi Watanabe et al. Lung Cancer. 2019 Jun.

Free article

. 2019 Jun:132:157-158.

doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20.

Authors

Affiliations

¹ Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, 8050 Ikarashi 2-no-cho, Nishi-ku, Niigata, 950-2181, Japan.
² Department of Respiratory Medicine, Kurashiki Central Hospital, 1 Chome-1-1 Miwa, Kurashiki, 710-8602, Japan.
³ Division of Thoracic Oncology, Saitama Cancer Center, 780 Komuro, Ina, Kitaadachi District, Saitama, 362-0806, Japan.
⁴ Department of Allergy and Respiratory Medicine, Center for Innovative Clinical Medicine, Okayama University Hospital, 2 Chome-5-1 Shikatacho, Kita, Okayama, 700-8558, Japan.
⁵ Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 3 Chome-1-1 Notame, Minami Ward, Fukuoka, 811-1395, Japan.
⁶ Department of Internal Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume, Fukuoka Prefecture, 830-0011, Japan.
⁷ Department of Pulmonary Medicine, Sendai Kousei Hospital, 4-15 Hirosemachi, Aoba Ward, Sendai, Miyagi Prefecture, 980-0873, Japan.
⁸ Department of Medical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
⁹ Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3 Chome-18-22, Bunkyō-ku, Honkomagome, 113-0021, Tokyo, Japan.
¹⁰ Department of Respiratory Medicine, Kobe City Medical Center General Hospital, 2 Chome-1-1 Minatojima Minamimachi, Chuo Ward, Kobe, Hyōgo Prefecture, 650-0047, Japan.
¹¹ Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba-ken, 277-8577, Japan.
¹² Third Department of Internal Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, WakayamaPrefecture, 641-8509, Japan.
¹³ Department of Thoracic Medical Oncology, Japanese Foundation for Cancer Research, Cancer Institute Hospital, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.
¹⁴ Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
¹⁵ Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6 Chome-16-1 Tomiokahigashi, Kanazawa-ku, Yokohama-shi, Kanagawa, 236-0051, Japan.
¹⁶ Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
¹⁷ Medical Affairs, Eli Lilly Japan K.K., 7-1-5 Isogamidori, Chuo-Ku, Kobe, 651-0086, Japan.
¹⁸ Department of Medical Oncology, Kindai University Faculty of Medicine, 3-4-1 Kowakae, Higashiosaka City, Osaka, 577-8502, Japan.
¹⁹ Thoracic Center, St. Luke's International Hospital, 9-1 Akashicho, Chuo-ku, Tokyo, 104-8560, Japan. Electronic address: tamuratomohide@gmail.com.

PMID: 31014853
DOI: 10.1016/j.lungcan.2019.04.010

No abstract available

PubMed Disclaimer

Erratum for

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T. Watanabe S, et al. Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16. Lung Cancer. 2019. PMID: 30797492 Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62]

Affiliations

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62]

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources